Our Drug Development Partner Network

Clinical supply doesn't exist on its own. Programs also need CMC development, analytical expertise, discovery support, and contamination control. Brizzey works with a network of selected partner organizations that provide the drug development services our clients need but that fall outside our own expertise. These are established, long-term relationships, so your program gets seamless execution from one coordinated team.

Ultramikro, LLC
Contamination Control and Pharmacopeial Compliance
Ultramikro, LLC is a consulting firm that guides the pharmaceutical and food industries on contamination control and global pharmacopeial compliance. Particulate matter in the pharmaceutical presentation may be foreign material or may form due to substances intrinsic to the formulation or package. Removing sub-visible (less than 100μm) and larger particles, or reducing their impact, depends on identifying them, which is facilitated by analysis using a variety of instruments and approaches. Microscopical applications are foremost in the Ultramikro approach.
The collaboration between Brizzey and Ultramikro ensures that the skills necessary to solve unexpected challenges during product development are available when needed.
Vermeer Pharma, LLC

CMC Drug Development
Mark VanArendonk founded Vermeer Pharma, LLC in 2018. He has more than 30 years of pharmaceutical experience and specializes in CMC drug development. During his “big pharma” career, Mark held positions of increasing responsibility in Analytical R&D, Quality Assurance, and CMC at various companies, culminating in his role as Merck Vice President for Analytical Chemistry in Development and Supply, where he was responsible for late-stage development programs from IIB through registration, launch, and commercialization. As an independent consultant, Dr. VanArendonk supports small and medium-sized companies in early and late development.
We believe that the partnership between Brizzey and Vermeer Pharma brings together a dynamic combination of skills and experience that will facilitate our clients’ pathway to end-to-end development and increase the rate at which they can bring medicines to patients.

Synergy Partners R&D Solutions
Discovery Through Clinical Proof of Concept
Synergy Partners R&D Solutions is a network of scientists with deep experience across all aspects of pharmaceutical research and development, from target selection to clinical proof of concept and beyond. They have a track record of turning exciting discoveries into medicines by partnering with clients to design and implement the optimal development strategy for each molecule. Synergy can support you across all aspects of drug discovery and development, including biology, pharmacology, chemistry, drug safety, DMPK, clinical, and regulatory. Synergy will work with your team to design and oversee appropriate testing and integrate the knowledge gained into downstream plans to position your program for a seamless transition to development.
The collaboration between Brizzey and Synergy Partners brings broad expertise to your research and development programs and enables a seamless transition from research to development.
FarmCMC
FarmCMC
Product Development and Delivery Systems
John Skoug founded FarmCMC in 2019 to leverage his technical and leadership expertise to help small and medium-sized biopharmaceutical companies develop novel therapeutic assets and delivery systems through early and late stages.
John has more than 30 years of pharmaceutical industry experience and specializes in CMC product development across all stages of discovery and development. Prior to founding Farm CMC, he was Senior Director in AbbVie’s drug product R&D organization. There, he held several roles, where he led CMC technical strategy and execution for small molecule programs and combination product programs for biologics. John brings a unique breadth of CMC experience, including pharmaceutics support for discovery teams and drug and device delivery system technology assessment.
Together, Brizzey and FarmCMC offer a complementary set of skills and experience, which can help clients with a broad range of activities essential to the development of novel therapeutic assets and delivery systems.